NO320366B1 - Vandige risperidonformuleringer - Google Patents

Vandige risperidonformuleringer Download PDF

Info

Publication number: NO320366B1
Authority: NO; Norway
Prior art keywords: solution; risperidone; range; water; solution according
Prior art date: 1994-07-11

Application number

NO19970051A

Other languages

English (en)

Norwegian (no)

Other versions

NO970051L (no

NO970051D0 (no

Inventor

Willy Maria Albert Carlo Dries

Marc Karel Jozef Francois

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-11

Filing date

1997-01-07

Publication date

2005-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO320366(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-01-07 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1997-01-07 Publication of NO970051L publication Critical patent/NO970051L/no

1997-01-07 Publication of NO970051D0 publication Critical patent/NO970051D0/no

2005-11-28 Publication of NO320366B1 publication Critical patent/NO320366B1/no

Links

RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 35
229960001534 risperidone Drugs 0.000 title claims abstract description 34
239000000203 mixture Substances 0.000 title claims abstract description 30
238000009472 formulation Methods 0.000 title description 6
238000000034 method Methods 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 6
238000007911 parenteral administration Methods 0.000 claims abstract description 5
239000007864 aqueous solution Substances 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 39
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 14
239000000872 buffer Substances 0.000 claims description 13
239000003755 preservative agent Substances 0.000 claims description 13
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 10
229940100688 oral solution Drugs 0.000 claims description 9
239000011975 tartaric acid Substances 0.000 claims description 9
235000002906 tartaric acid Nutrition 0.000 claims description 9
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
239000000600 sorbitol Substances 0.000 claims description 8
239000005711 Benzoic acid Substances 0.000 claims description 7
235000010233 benzoic acid Nutrition 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
239000003182 parenteral nutrition solution Substances 0.000 claims description 7
230000002335 preservative effect Effects 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
238000003756 stirring Methods 0.000 claims description 7
239000000796 flavoring agent Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
235000003599 food sweetener Nutrition 0.000 claims description 5
239000003765 sweetening agent Substances 0.000 claims description 5
239000011780 sodium chloride Substances 0.000 claims description 4
238000007865 diluting Methods 0.000 claims description 3
238000004090 dissolution Methods 0.000 claims description 3
238000001816 cooling Methods 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
229960001367 tartaric acid Drugs 0.000 description 5
-1 1,2-benzisoxazol-3-yl Chemical class 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 4
239000002585 base Substances 0.000 description 4
235000019634 flavors Nutrition 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
150000005846 sugar alcohols Polymers 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000007958 cherry flavor Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
229960002216 methylparaben Drugs 0.000 description 3
229940127557 pharmaceutical product Drugs 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
229960003415 propylparaben Drugs 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
KSWIOGDSXUFKOC-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 KSWIOGDSXUFKOC-LREBCSMRSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
235000011034 Rubus glaucus Nutrition 0.000 description 2
244000235659 Rubus idaeus Species 0.000 description 2
235000009122 Rubus idaeus Nutrition 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229960000448 lactic acid Drugs 0.000 description 2
235000019629 palatability Nutrition 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
239000012453 solvate Substances 0.000 description 2
235000010199 sorbic acid Nutrition 0.000 description 2
239000004334 sorbic acid Substances 0.000 description 2
229940075582 sorbic acid Drugs 0.000 description 2
235000019640 taste Nutrition 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
244000171263 Ribes grossularia Species 0.000 description 1
235000002357 Ribes grossularia Nutrition 0.000 description 1
240000001890 Ribes hudsonianum Species 0.000 description 1
235000016954 Ribes hudsonianum Nutrition 0.000 description 1
235000001466 Ribes nigrum Nutrition 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
235000010358 acesulfame potassium Nutrition 0.000 description 1
229960004998 acesulfame potassium Drugs 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
150000008316 benzisoxazoles Chemical class 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
NNOYLBKZPCUCQT-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-3-olate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 NNOYLBKZPCUCQT-UHFFFAOYSA-L 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000008370 chocolate flavor Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000008369 fruit flavor Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000013615 non-nutritive sweetener Nutrition 0.000 description 1
229940098462 oral drops Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
239000007967 peppermint flavor Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000010333 potassium nitrate Nutrition 0.000 description 1
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Inorganic materials [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
229960001462 sodium cyclamate Drugs 0.000 description 1
235000014214 soft drink Nutrition 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO19970051A 1994-07-11 1997-01-07 Vandige risperidonformuleringer NO320366B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/272,462 US5453425A (en)	1994-07-11	1994-07-11	Risperidone oral formulation
US08/429,435 US5616587A (en)	1994-07-11	1995-04-26	Aqueous risperidone formulations
PCT/EP1995/002615 WO1996001652A1 (en)	1994-07-11	1995-07-04	Aqueous risperidone formulations

Publications (3)

Publication Number	Publication Date
NO970051L NO970051L (no)	1997-01-07
NO970051D0 NO970051D0 (no)	1997-01-07
NO320366B1 true NO320366B1 (no)	2005-11-28

Family

ID=26955530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19970051A NO320366B1 (no)	1994-07-11	1997-01-07	Vandige risperidonformuleringer

Country Status (36)

Country	Link
US (3)	US5453425A (ja)
EP (1)	EP0769965B1 (ja)
JP (1)	JP2872412B2 (ja)
KR (1)	KR100212942B1 (ja)
CN (1)	CN1148226C (ja)
AP (1)	AP774A (ja)
AT (1)	ATE206931T1 (ja)
AU (1)	AU684193B2 (ja)
BG (1)	BG63070B1 (ja)
BR (1)	BR9508253A (ja)
CA (1)	CA2194564C (ja)
CY (1)	CY2268B1 (ja)
CZ (1)	CZ285204B6 (ja)
DE (1)	DE69523313T2 (ja)
DK (1)	DK0769965T3 (ja)
EE (1)	EE03426B1 (ja)
ES (1)	ES2165918T3 (ja)
FI (1)	FI116510B (ja)
HR (1)	HRP950397B1 (ja)
HU (1)	HU222352B1 (ja)
IL (1)	IL114525A (ja)
MX (1)	MX9700374A (ja)
MY (1)	MY114389A (ja)
NO (1)	NO320366B1 (ja)
NZ (1)	NZ289432A (ja)
PH (1)	PH31626A (ja)
PL (1)	PL179972B1 (ja)
PT (1)	PT769965E (ja)
RO (1)	RO116778B1 (ja)
RU (1)	RU2161965C2 (ja)
SI (1)	SI9500220B (ja)
SK (1)	SK282159B6 (ja)
TR (1)	TR199500778A1 (ja)
TW (1)	TW420615B (ja)
WO (1)	WO1996001652A1 (ja)
ZA (1)	ZA955720B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1074923C (zh)	1993-11-19	2001-11-21	詹森药业有限公司	微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5453425A (en) *	1994-07-11	1995-09-26	Janssen Pharmaceutica N.V.	Risperidone oral formulation
UA72189C2 (uk) *	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en)	1998-12-22	2004-01-27	The United States Of America As Represented By The Department Of Health And Human Services	Water-insoluble drug delivery system
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
SE0103211D0 (sv) *	2001-09-27	2001-09-27	Pharmacia Ab	New formulations and use thereof
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20060148826A1 (en) *	2002-08-23	2006-07-06	Ashish Gogia	Stable aqueous solutions of risperidone and methods for their preparation
WO2004094415A1 (en) *	2003-04-22	2004-11-04	Synthon B.V.	Risperidone monohydrochloride
PE20050285A1 (es)	2003-06-24	2005-06-09	Novartis Ag	Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US20050036977A1 (en) *	2003-08-11	2005-02-17	Dilip Gole	Taste-masked resinate and preparation thereof
ES2245252B1 (es) *	2004-06-15	2007-03-01	Farmalider, S.A.	Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) *	2004-07-09	2006-11-16	Clinmet S.L.	"metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) *	2005-06-01	2006-12-07	Aurobindo Pharma Limited	Stable aqueous oral solution of risperidone
ATE424399T1 (de) *	2005-06-29	2009-03-15	Verisfield Uk Ltd	Pharmazeutische zusammensetzungen von risperidon in wässriger lösung
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
JP4922657B2 (ja) *	2006-05-09	2012-04-25	高田製薬株式会社	リスペリドン経口用液剤
WO2007138462A2 (en) *	2006-06-01	2007-12-06	Wockhardt Ltd	Aqueous oral formulations of risperidone
EP2152315B1 (en)	2007-05-25	2016-01-06	Indivior UK Limited	Sustained delivery formulations of risperidone compounds
US7776866B2 (en) *	2007-09-15	2010-08-17	Protia, Llc	Deuterium-enriched risperidone
BRPI0821408A2 (pt) *	2007-12-19	2015-06-16	Janssen Pharmaceutica Nv	Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
CN102292094B (zh)	2009-01-20	2013-08-14	洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心	增强神经药方疗效的山梨酸与苯甲酸及其衍生物
US9272044B2 (en)	2010-06-08	2016-03-01	Indivior Uk Limited	Injectable flowable composition buprenorphine
GB2481017B (en)	2010-06-08	2015-01-07	Rb Pharmaceuticals Ltd	Microparticle buprenorphine suspension
AU2012321345B2 (en) *	2011-10-03	2016-03-17	The University Of Utah Research Foundation	Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en)	2014-03-10	2014-04-23	Rb Pharmaceuticals Ltd	Sustained release buprenorphine solution formulations
NZ731309A (en)	2014-11-07	2022-02-25	Indivior Uk Ltd	Buprenorphine dosing regimens
ES2936094T3 (es)	2016-06-13	2023-03-14	Syneurx Int Taiwan Corp	Cocristales de benzoato de sodio y usos de los mismos
RU2765625C2 (ru)	2016-06-13	2022-02-01	Сайньюрекс Интернэшнл (Тайвань) Корп.	Сокристаллы бензоата лития и их применения
CN109890365A (zh) *	2016-09-23	2019-06-14	戴尔普尔有限公司	小分子治疗剂化合物的组合物
US10336679B2 (en)	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
RU2646812C1 (ru) *	2016-10-24	2018-03-07	Общество с ограниченной ответственностью "Трейдсервис"	Жидкая лекарственная форма рисперидона и способ ее получения
US11369579B2 (en)	2016-10-24	2022-06-28	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US10646484B2 (en)	2017-06-16	2020-05-12	Indivior Uk Limited	Methods to treat opioid use disorder
CN107260662A (zh) *	2017-06-21	2017-10-20	南京正科医药股份有限公司	一种利培酮口服溶液及其制备方法
CN107441037A (zh) *	2017-08-16	2017-12-08	南京正科医药股份有限公司	一种利培酮口服溶液
CN109589304A (zh) *	2017-10-01	2019-04-09	万特制药(海南)有限公司	利培酮口服溶液及其制备方法
US10098861B1 (en)	2017-10-24	2018-10-16	Syneurx International (Taiwan) Corp.	Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
JP2021515038A (ja) *	2018-02-27	2021-06-17	デルポー・インコーポレイテッドＤｅｌｐｏｒ，Ｉｎｃ．	小分子治療剤化合物のための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4337261A (en) *	1980-07-28	1982-06-29	Hoechst-Roussel Pharmaceuticals Inc.	(1,2-Benzisoxazol)phenoxyacetic acids as diuretics
US4793992A (en) *	1987-03-25	1988-12-27	Redken Laboratories, Inc.	Hair treatment composition
IL88233A (en) *	1987-11-03	1993-08-18	Genentech Inc	Gamma interferon formulation
FR2641278B1 (fr) *	1989-01-05	1991-03-22	Lipha	Piperidines, procedes de preparation et medicaments les contenant
DK203990D0 (da) *	1990-08-24	1990-08-24	Novo Nordisk As	Piperazinylderivater
TW376319B (en) *	1993-04-28	1999-12-11	Janssen Pharmaceutica Nv	Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) *	1994-07-11	1995-09-26	Janssen Pharmaceutica N.V.	Risperidone oral formulation
FR2796273B1 (fr) *	1999-07-15	2003-09-12	Oreal	Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

1994
- 1994-07-11 US US08/272,462 patent/US5453425A/en not_active Expired - Lifetime
1995
- 1995-04-26 US US08/429,435 patent/US5616587A/en not_active Ceased
- 1995-05-19 TW TW084104959A patent/TW420615B/zh not_active IP Right Cessation
- 1995-05-31 PH PH50624A patent/PH31626A/en unknown
- 1995-06-29 TR TR95/00778A patent/TR199500778A1/xx unknown
- 1995-07-04 HU HU9700082A patent/HU222352B1/hu active IP Right Grant
- 1995-07-04 RO RO97-00032A patent/RO116778B1/ro unknown
- 1995-07-04 EP EP95924978A patent/EP0769965B1/en not_active Expired - Lifetime
- 1995-07-04 DE DE69523313T patent/DE69523313T2/de not_active Expired - Lifetime
- 1995-07-04 PL PL95318132A patent/PL179972B1/pl unknown
- 1995-07-04 BR BR9508253A patent/BR9508253A/pt not_active IP Right Cessation
- 1995-07-04 SK SK22-97A patent/SK282159B6/sk not_active IP Right Cessation
- 1995-07-04 AP APAP/P/1997/000910A patent/AP774A/en active
- 1995-07-04 MX MX9700374A patent/MX9700374A/es unknown
- 1995-07-04 RU RU97102139/14A patent/RU2161965C2/ru active
- 1995-07-04 KR KR1019970700039A patent/KR100212942B1/ko not_active Expired - Lifetime
- 1995-07-04 NZ NZ289432A patent/NZ289432A/en not_active IP Right Cessation
- 1995-07-04 EE EE9700009A patent/EE03426B1/xx unknown
- 1995-07-04 CN CNB951940821A patent/CN1148226C/zh not_active Expired - Lifetime
- 1995-07-04 ES ES95924978T patent/ES2165918T3/es not_active Expired - Lifetime
- 1995-07-04 WO PCT/EP1995/002615 patent/WO1996001652A1/en not_active Ceased
- 1995-07-04 JP JP8504108A patent/JP2872412B2/ja not_active Expired - Lifetime
- 1995-07-04 PT PT95924978T patent/PT769965E/pt unknown
- 1995-07-04 DK DK95924978T patent/DK0769965T3/da active
- 1995-07-04 CA CA002194564A patent/CA2194564C/en not_active Expired - Lifetime
- 1995-07-04 AT AT95924978T patent/ATE206931T1/de active
- 1995-07-04 AU AU29275/95A patent/AU684193B2/en not_active Expired
- 1995-07-04 CZ CZ9727A patent/CZ285204B6/cs not_active IP Right Cessation
- 1995-07-10 SI SI9500220A patent/SI9500220B/sl active Search and Examination
- 1995-07-10 IL IL11452595A patent/IL114525A/xx not_active IP Right Cessation
- 1995-07-10 ZA ZA955720A patent/ZA955720B/xx unknown
- 1995-07-10 HR HR950397A patent/HRP950397B1/xx not_active IP Right Cessation
- 1995-07-11 MY MYPI95001944A patent/MY114389A/en unknown
1997
- 1997-01-04 BG BG101106A patent/BG63070B1/bg unknown
- 1997-01-07 NO NO19970051A patent/NO320366B1/no not_active IP Right Cessation
- 1997-01-10 FI FI970109A patent/FI116510B/fi not_active IP Right Cessation
2001
- 2001-12-04 US US09/955,274 patent/USRE39181E1/en not_active Expired - Lifetime
2002
- 2002-04-25 CY CY0200019A patent/CY2268B1/xx unknown

Also Published As

Publication number	Publication date
NO970051L (no)	1997-01-07
DE69523313T2 (de)	2002-06-27
PT769965E (pt)	2002-04-29
FI970109L (fi)	1997-01-10
JP2872412B2 (ja)	1999-03-17
RO116778B1 (ro)	2001-06-29
HUT76826A (en)	1997-11-28
TR199500778A1 (tr)	1996-10-21
MX9700374A (es)	1997-04-30
CN1155247A (zh)	1997-07-23
IL114525A (en)	1999-06-20
CN1148226C (zh)	2004-05-05
AP9700910A0 (en)	1997-01-31
USRE39181E1 (en)	2006-07-11
HU222352B1 (hu)	2003-06-28
US5453425A (en)	1995-09-26
EP0769965A1 (en)	1997-05-02
EP0769965B1 (en)	2001-10-17
DE69523313D1 (de)	2001-11-22
CA2194564C (en)	1997-12-16
KR100212942B1 (ko)	1999-08-02
CZ285204B6 (cs)	1999-06-16
JPH09511751A (ja)	1997-11-25
CA2194564A1 (en)	1996-01-25
US5616587A (en)	1997-04-01
WO1996001652A1 (en)	1996-01-25
AU2927595A (en)	1996-02-09
PH31626A (en)	1999-01-12
SK2297A3 (en)	1997-09-10
TW420615B (en)	2001-02-01
FI970109A0 (fi)	1997-01-10
HRP950397B1 (en)	2002-04-30
EE9700009A (et)	1997-08-15
MY114389A (en)	2002-10-31
ATE206931T1 (de)	2001-11-15
ZA955720B (en)	1997-01-10
NZ289432A (en)	1998-05-27
HK1010691A1 (en)	1999-06-25
CZ2797A3 (en)	1997-07-16
IL114525A0 (en)	1995-11-27
BG63070B1 (bg)	2001-03-30
KR970704472A (ko)	1997-09-06
HRP950397A2 (en)	1997-10-31
SI9500220B (sl)	2004-12-31
BG101106A (en)	1997-08-29
FI116510B (fi)	2005-12-15
HU9700082D0 (en)	1997-02-28
BR9508253A (pt)	1997-12-23
EE03426B1 (et)	2001-06-15
SI9500220A (en)	1996-02-29
ES2165918T3 (es)	2002-04-01
DK0769965T3 (da)	2002-02-04
AP774A (en)	1999-10-28
RU2161965C2 (ru)	2001-01-20
SK282159B6 (sk)	2001-11-06
NO970051D0 (no)	1997-01-07
AU684193B2 (en)	1997-12-04
PL179972B1 (pl)	2000-11-30
CY2268B1 (en)	2003-07-04
PL318132A1 (en)	1997-05-12

Legal Events

Date	Code	Title	Description
2015-07-13	MK1K	Patent expired

Publication	Publication Date	Title
NO320366B1 (no)	2005-11-28	Vandige risperidonformuleringer
AU2008274170B2 (en)	2011-06-09	Oral pharmaceutical solutions containing telbivudine
NO177126B (no)	1995-04-18	Fremgangsmåte for fremstilling av et væskeformig farmasöytisk preparat for oral administrering
WO2006129160A2 (en)	2006-12-07	Stable aqueous oral solution of risperidone
US20060148826A1 (en)	2006-07-06	Stable aqueous solutions of risperidone and methods for their preparation
HK1010691B (en)	2002-03-08	Aqueous risperidone formulations
KR102242382B1 (ko)	2021-04-20	용해성, 안정성 및 쓴맛이 개선된 로라타딘 함유 시럽 조성물
WO2013062497A1 (en)	2013-05-02	Liquid pharmaceutical formulations
US20030104017A1 (en)	2003-06-05	Epinastine formulation for oral administration
ES2245252B1 (es)	2007-03-01	Solucion acuosa de risperidona para administracion oral.